eligibility_summary
Eligible: Adults with stage IV/recurrent NSCLC (adeno/squamous) planned for anti‑PD1, resectable, non‑irradiated tumor ≥1.5 cm and measurable disease post‑resection, ECOG ≤1, survival >6 mo, adequate organs, LVEF >50%, DLCO >50%. Exclude: prior metastatic PD1/PD‑L1 (adjuvant >6 mo OK), driver mutations, recent immunosuppression, active/symptomatic CNS or lepto mets, infections (IV abx ≤7 d, HIV/HBV/HCV, live vaccine ≤30 d), autoimmune/ILD, transplant, hypersensitivity, unresolved tox >G1, O2 >2 L, recent other cancer, pregnancy, contraception required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Interventions and mechanisms: 1) C-TIL051: autologous tumor-infiltrating lymphocyte (TIL) cell therapy (cellular immunotherapy). Patient tumor T cells are expanded ex vivo and reinfused after lymphodepleting chemotherapy to enhance engraftment, they mediate tumor-specific cytotoxicity. 2) NKTR-255: polymer-conjugated IL-15 receptor agonist (cytokine agonist) designed to increase proliferation, survival, and persistence of memory CD8+ T cells and support long-term immune memory. 3) Pembrolizumab: anti-PD-1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD-1 signaling to reinvigorate exhausted T cells. Targets/pathways: tumor-reactive CD8+ T cells, IL-15/IL-15R signaling to expand effector/memory T cells, PD-1/PD-L1 checkpoint axis, overall goal is enhanced T-cell cytotoxicity, persistence, and response in anti-PD-1–resistant metastatic NSCLC.